Roger S McIntyre1, Isabelle P Carvalho2, Leanna M W Lui2, Amna Majeed2, Prakash S Masand3, Hartej Gill2, Nelson B Rodrigues2, Orly Lipsitz2, Alexandria C Coles2, Yena Lee2, Jocelyn K Tamura2, Michelle Iacobucci2, Lee Phan2, Flora Nasri2, Nikhita Singhal4, Elizabeth R Wong2, Mehala Subramaniapillai2, Rodrigo Mansur2, Roger Ho5, Raymond W Lam6, Joshua D Rosenblat2. 1. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: roger.mcintyre@uhn.ca. 2. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. 3. Centers of Psychiatric Excellence, New York, NY, United States. 4. Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 5. Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore. 6. Department of Psychiatry, University of British Columbia, Vancouver, B.C., Canada.
Abstract
BACKGROUND: Ketamine is established as a rapid and effective treatment in adults with treatment-resistant depression (TRD). The availability of different formulations and routes of delivery invites the need for evaluating relative effect sizes. METHODS: Effect size with respect to depression symptom reduction for each formulation and route of delivery was compared at discrete time-points (i.e., 24 h, 2-6 days, 7-20 days, 21-28 days) in adults with TRD. A random-effects meta-analysis was conducted to evaluate the effect size across intravenous, intranasal and oral routes of administration. Analysis was also conducted evaluating the effect size of racemic ketamine to esketamine. RESULTS: The pooled effect size for intranasal ketamine/esketamine at 24 h was g = 1.247 (n = 5, 95% CI: 0.591-1.903, p < 0.01). At 2-6 days, the pooled effect size for intravenous ketamine/esketamine was g = 0.949 (n = 14, 95% CI: -0.308-2.206, p = 0.139). At 7-20 days, intranasal ketamine had a pooled effect size of g = 1.018 (n = 4, 95% CI: 0.499-1.538, p < 0.01). At 21-28 days, oral ketamine had a pooled effect size of g = 0.633 (n = 2, 95% CI: 0.368-0.898, p < 0.01). LIMITATIONS: Additional comparative studies are needed with regards to the efficacy of different formulations and routes of delivery. CONCLUSIONS: The short-term efficacy of intravenous and intranasal ketamine/esketamine for adults with TRD was established. Interpreting the efficacy of oral ketamine was limited by the need for studies with larger samples across independent sites. No conclusions regarding comparative efficacy of the disparate formulations and routes of delivery can be derived from this analysis. Direct comparative studies are needed to further inform treatment options for TRD.
BACKGROUND:Ketamine is established as a rapid and effective treatment in adults with treatment-resistant depression (TRD). The availability of different formulations and routes of delivery invites the need for evaluating relative effect sizes. METHODS: Effect size with respect to depression symptom reduction for each formulation and route of delivery was compared at discrete time-points (i.e., 24 h, 2-6 days, 7-20 days, 21-28 days) in adults with TRD. A random-effects meta-analysis was conducted to evaluate the effect size across intravenous, intranasal and oral routes of administration. Analysis was also conducted evaluating the effect size of racemic ketamine to esketamine. RESULTS: The pooled effect size for intranasal ketamine/esketamine at 24 h was g = 1.247 (n = 5, 95% CI: 0.591-1.903, p < 0.01). At 2-6 days, the pooled effect size for intravenous ketamine/esketamine was g = 0.949 (n = 14, 95% CI: -0.308-2.206, p = 0.139). At 7-20 days, intranasal ketamine had a pooled effect size of g = 1.018 (n = 4, 95% CI: 0.499-1.538, p < 0.01). At 21-28 days, oral ketamine had a pooled effect size of g = 0.633 (n = 2, 95% CI: 0.368-0.898, p < 0.01). LIMITATIONS: Additional comparative studies are needed with regards to the efficacy of different formulations and routes of delivery. CONCLUSIONS: The short-term efficacy of intravenous and intranasal ketamine/esketamine for adults with TRD was established. Interpreting the efficacy of oral ketamine was limited by the need for studies with larger samples across independent sites. No conclusions regarding comparative efficacy of the disparate formulations and routes of delivery can be derived from this analysis. Direct comparative studies are needed to further inform treatment options for TRD.
Authors: Rebecca B Price; Nicholas Kissel; Andrew Baumeister; Rebecca Rohac; Mary L Woody; Elizabeth D Ballard; Carlos A Zarate; William Deakin; Chadi G Abdallah; Adriana Feder; Dennis S Charney; Michael F Grunebaum; J John Mann; Sanjay J Mathew; Bronagh Gallagher; Declan M McLoughlin; James W Murrough; Suresh Muthukumaraswamy; Rebecca McMillan; Rachael Sumner; George Papakostas; Maurizio Fava; Rebecca Hock; Jennifer L Phillips; Pierre Blier; Paulo Shiroma; Peter Šóš; Tung-Ping Su; Mu-Hong Chen; Mikael Tiger; Johan Lundberg; Samuel T Wilkinson; Meredith L Wallace Journal: Mol Psychiatry Date: 2022-09-07 Impact factor: 13.437
Authors: Nicolas A Nuñez; Boney Joseph; Mehak Pahwa; Ashok Seshadri; Larry J Prokop; Simon Kung; Kathryn M Schak; Jennifer L Vande Voort; Mark A Frye; Balwinder Singh Journal: Psychopharmacol Bull Date: 2020-09-14
Authors: Eric P McMullen; Yena Lee; Orly Lipsitz; Leanna M W Lui; Maj Vinberg; Roger Ho; Nelson B Rodrigues; Joshua D Rosenblat; Bing Cao; Hartej Gill; Kayla M Teopiz; Danielle S Cha; Roger S McIntyre Journal: Adv Ther Date: 2021-04-30 Impact factor: 3.845
Authors: Felicia Ceban; Joshua D Rosenblat; Kevin Kratiuk; Yena Lee; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Flora Nasri; Leanna M W Lui; Orly Lipsitz; Anil Kumar; Jung Goo Lee; Edmond H Chau; Bing Cao; Kangguang Lin; Roger C Ho; Rodrigo B Mansur; Jennifer Swainson; Roger S McIntyre Journal: CNS Drugs Date: 2021-08-07 Impact factor: 5.749